Guillain-Barre Syndrome Amid Osteosarcoma Treatment: A Therapeutic Dilemma and Literature Review

Geraldine Peralta Suarez 1, David W. Deng 2, Raquel Silva 3, Gabriel Tinoco 2

1. Internal Medicine, Universidad Militar Nueva Granada, Bogota, COL 2. Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, USA 3. Physical Medicine and Rehabilitation, OhioHealth, Columbus, USA

Corresponding author: Gabriel Tinoco, gabriel.tinoco@osumc.edu

Abstract
Guillain-Barre syndrome (GBS) is a clinical syndrome with multiple variants. GBS is defined as an acute demyelinating polyneuropathy commonly preceded by infection (bacterial or viral), trauma, or inflammatory processes, which triggers an autoimmune response that affects the peripheral nervous system. This case report describes a patient with high-grade osteosarcoma that completed neoadjuvant chemotherapy and underwent surgical resection with no immediate complications. Fourteen days after the surgery, the patient developed an acute inflammatory demyelinating polyradiculopathy consistent with GBS. As the five-year survival without chemotherapy is only around 20%, this challenging clinical scenario raised questions regarding adjuvant chemotherapy’s safe completion in this setting.

Introduction
Guillain–Barre syndrome (GBS) is defined as an acute demyelinating polyneuropathy, which is currently best understood as a monophasic autoimmune condition affecting the peripheral nerves [1]. It is thought that GBS’s pathophysiology is related to both cell-mediated and humoral immunity [2]. The incidence in Europe and North America is roughly 0.16-4/100.000 habitants per year and 0.5-1.5/100.000 habitants per year in adults and children, respectively. The highest rates are seen in the elderly (>80 years) and are usually 1.5 times more common in males than females. Frequently patients describe symptoms like fever (52%), cough (48%), sore throat (39%), nasal discharge (30%), and diarrhea 2-4 weeks before the onset of GBS [1, 2].

The clinical spectrum of Guillain-Barré syndrome is wide-ranged. Multiple variants have been identified: acute inflammatory demyelinating polyneuropathy (AIDP) and axonal subtypes - acute motor axonal neuropathy (AMAN) and acute motor and sensory axonal neuropathy (AMSAN). The clinical features of those types of GBS are similar. However, the course is faster and more severe in the axonal form, which also more frequently causes both respiratory and cranial nerve involvement and less frequently causes dysautonomia [2].

Bacterial infections are most commonly associated with GBS, most notably Campylobacter jejuni (C. jejuni). The pathophysiology of prior C. jejuni infection-causing GBS is explained in the literature by molecular mimicry between C. jejuni lipoooligosaccharide and gangliosides (which are abundant in nervous tissue) [1, 2]. Certain other conditions have been proposed as possibly predisposing patients to GBS, including vaccination, surgery, bone marrow transplant, cancer, and chemotherapy [2].

Cases of GBS have been reported after administration of a single vaccine or combination of two vaccines. The highest rate of cases was observed after the swine influenza vaccination in 1976-1977. Five hundred thirty-two patients received influenza vaccination in New Jersey before the onset of the Guillain-Barre symptoms. This vaccine contained contaminating residues that triggered an autoimmune response against GM1 in the host. The mean interval from vaccination to onset of symptoms was 3.9 weeks, and the estimated risk of vaccine-related GBS in adults was roughly one case per 100,000 vaccinations. The second most frequently reported cause post-vaccination GBS was hepatitis vaccination (nine out of 54 patients). The association with tetanus and diphtheria toxoid vaccine was found in a lower proportion (one out of 54 patients). However, current literature suggests that the presentation of GBS after vaccination is extremely rare [3].

Mayo Clinic conducted a trial in which 208 patients were diagnosed with GBS within six weeks after surgery. It was found that comorbid autoimmune disease was associated with the development of post-surgical GBS. Cancer patients were more susceptible to develop GBS, with a reported prevalence of 2.4 times higher than the general population. It has been hypothesized that surgery produces transient immunosuppression that...
Our patient met the Brighton criteria for Guillain–Barre’s diagnosis (level 1 of diagnostic certainty). To our
discussion, recurrence from osteosarcoma or GBS.

He completed his adjuvant chemotherapy with minimal side effects. He continued his
continued cisplatin use, it was decided to complete his adjuvant chemotherapy with single-agent
doxorubicin. The chemotherapy was started 12 weeks after the initial presentation in the emergency
clinic setting. He was discharged from the hospital and received an extensive inpatient rehabilitation program, with

Clinically, his neurological symptoms stabilized, and due to the concern for worsening neuropathy with the
continued cisplatin use, it was decided to complete his adjuvant chemotherapy with single-agent
doxorubicin. The chemotherapy was started 12 weeks after the initial presentation in the emergency
department. He completed his adjuvant chemotherapy with minimal side effects. He continued his
rehabilitation and was able to regain the ability of daily living activities independently, and to date, he has
successfully participated in four half marathons. Thirty months after his surgery, there is no evidence of
recurrence from osteosarcoma or GBS.

Discussion

Our patient met the Brighton criteria for Guillain–Barre’s diagnosis (level 1 of diagnostic certainty). To our
knowledge, this is the first case reported of GBS occurring in an adult patient receiving curative treatment for high-grade osteosarcoma. It is not clear the exact trigger of GBS; however, associated factors include chemotherapy, surgery, and the malignancy itself [1, 2, 4].

Cisplatin is notorious for causing neuropathy as one of its adverse effects [10]. This neuropathy is described as an axonal, mostly sensory polyneuropathy, classically involving a ‘stocking-glove distribution’ which is different and much more benign than the more typical presentation of GBS. Yet, it should be noticed GBS infrequently can present as ascending paralysis in a ‘stocking-glove distribution’ [11]. There are case reports of GBS occurring after treatment with platinum-based chemotherapy in patients with solid organ cancers, notably endometrium, lung, and colon cancer [6, 12, 13]. Reported cases of chemotherapy-associated GBS are presented in Table 1.

| Chemotherapy regimen                           | Cumulative dose | Onset of symptoms | Signs and symptoms                                                                 |
|-----------------------------------------------|-----------------|-------------------|----------------------------------------------------------------------------------|
| Cisplatin                                     | 240 mg/m2       | 30 days           | Lower limb weakness, mild distal upper limb weakness, ankle and knee reflexes absent, sensory impairment in soles |
| Cisplatin and gemcitabine                     | 144 mg and 1800 mg | Six days          | Tetraparesis, lower limb areflexia, facial palsy                               |
| Cisplatin, etoposide, and bleomycin           | 300 mg/m2, 1500 mg/m2, and 270 mg | Seven days | Tetraparesis, hypoesthesia, generalized areflexia, dyspnea, micturition impairment |
| Bevacizumab                                   | Unclear         | 30 days           | Tetraparesis, dyspnea, generalized areflexia, swallowing disturbance             |
| Pazopanib                                     | 800 mg/day for 34 days | 30 days          | Symmetrical distal limb weakness, sensory disturbance, areflexia                 |
| Cisplatin, doxorubicin, and cyclophosphamide (CAP) | Unclear         | After six cycles of CAP | Ascending paralysis, absence of deep tendon reflexes. |

**TABLE 1: Reported cases of chemotherapy-associated Guillain-Barre syndrome**

Pappa et al. directed a study of 449 patients diagnosed with peripheral neuropathies between 2012 and 2019. Five patients met the Brighton criteria for GBS diagnosis, and all patients had received platinum for the treatment of their tumors. They found that in all five cases, the cumulative platinum doses were below the established threshold for neurological toxicity (less than 300-450 mg/m2 of cisplatin). Patients presented marked motor compromise and disability for walking at the peak of disease severity. This compromise is consistent with GBS’s clinical features vs. toxic peripheral neuropathy, characterized by sensory ataxia and distal painful paresthesias [16].

There is also a case report of GBS occurring after doxorubicin-based chemotherapy. With our patient’s GBS 47 days after receiving doxorubicin and cisplatin, it does not exactly fit in with the case reports that cite GBS occurring after cisplatin chemotherapy (reported as happening as 1–2 weeks after chemotherapy). However, the case report by Terenghi et al. [17] does report initial symptoms presenting six weeks after treatment containing doxorubicin. To date, the use of single-agent Adriamycin has not been linked with GBS.

In another case of GBS after treatment with doxorubicin, bleomycin, vincristine, and dacarbazine (ABVD), it was decided to hold vincristine for one cycle and reduce the dose in another before reintroducing it at the full dose in the last cycle. It remains unclear the optimal chemotherapy regimen for adult patients with localized high-grade osteosarcoma. Still, in general, high-dose methotrexate (younger adults), doxorubicin, cisplatin, and ifosfamide are used [8].

The completion of adjuvant chemotherapy is paramount for treating high-grade osteosarcoma, as the five-year survival without chemotherapy is only around 20% [8, 9]. This challenging case raises a clinical dilemma: could adjuvant chemotherapy be safely completed despite a very recent occurrence of GBS? Or avoiding further chemotherapy and therefore reducing the osteosarcoma cure rate to avoid possible GBS recurrence is warranted?

After an exhaustive review of the literature, and extensive discussion with the patient and his family as well as our multidisciplinary sarcoma team, it was decided to discontinue cisplatin to avoid worsening neuropathy, and we decided to proceed with adjuvant single-agent doxorubicin, as historically anthracyclines constitute the backbone of the high-grade osteosarcoma [8]. To date, no studies have been published for patients with high-grade osteosarcoma, demonstrating alternative adjuvant treatments with similar efficacy compared to the standard of care nor the outcomes of patients that did not receive adjuvant...
cisplatin.

One study describes an increase in cancer incidence in patients with GBS vs. patients without GBS, suggesting a possible association [19]. The study also evidenced the possibility of GBS as a paraneoplastic syndrome; however, this has never been reported in osteosarcoma patients [20]. Our patient did not show any evidence of paraneoplastic syndrome.

It has been hypothesized that tumors could produce antigens that cause autoimmunity against the peripheral nerves; this is seen in notable paraneoplastic syndromes that affect the nervous system [15]. Another hypothesis suggests that the relative immunosuppression related to cancer or its treatment could lead to GBS through immune regulation defects [15]. The underpinnings of the possible immune-mediated mechanisms remain unclear at the present time.

The medical literature also reports an increased incidence of GBS in patients after surgery than patients not undergoing surgery [1, 2, 4, 5]. However, the incidence is exceedingly low compared to the incidence of GBS after well-known infectious triggers. It has been hypothesized that transient relative immunosuppression from the release of endogenous glucocorticoids after surgery may explain this increased incidence [2]. In our patient, the onset of symptoms occurred only two weeks after surgery, making surgery highly unlikely as the triggering event for GBS.

Conclusions
GBS is a rare and often devastating entity, with unclear physiopathology, variable presentation, and limited treatment options. To our knowledge, this is the first case reported of GBS occurring in an adult patient receiving curative treatment for high-grade osteosarcoma. Anthracycline-based chemotherapies could be administered with caution once GBS is in the recovery phase. The risks and benefits of the therapy should be thoroughly discussed with the patient and a multidisciplinary team.

Additional Information
Disclosures
Human subjects: Consent was obtained by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Acknowledgements
This work was funded in part by the National Cancer Institute grant K12CA133250.

References
1. Wijdicks EF, CJ Klein: Guillain-Barre syndrome. Mayo Clin Proc. 2017, 92:467-479. 10.1016/j.mayocp.2016.12.002
2. Fujimura H: The Guillain-Barré syndrome. Handb Clin Neurol. 2013, 115:385-402. 10.1016/B978-0-444-525902-2.00021-7
3. Souayah N, Nasar A, Suri MF, Qureshi AI: Guillain-Barre syndrome after vaccination in United States a report from the CDC/FDA Vaccine Adverse Event Reporting System. Vaccine. 2007, 25:5253-5255. 10.1016/j.vaccine.2007.05.053
4. Hoeker S, Nagaraian E, Rubin M, Wijdicks EFM: Clinical factors associated with Guillain-Barré syndrome following surgery. Neuro Clin Pract. 2018, 8:201-206. 10.1212/CNP.0000000000000451
5. Rudant J, Dupont A, Mikaeloff Y, et al.: Surgery and risk of Guillain-Barré syndrome: a French nationwide epidemiologic study. Neurology. 2018, 91:1220-1227. 10.1212/WNL.0000000000006246
6. Tho LM, O’Leary CP, Horrocks I, Al-Ani A, Reed NS: Guillain-Barre syndrome occurring after adjuvant chemo-radiotherapy for endometrial cancer. Gynecol Oncol. 2006, 100:615-617. 10.1016/j.ygyno.2005.09.008
7. Verdonk RC, Enting RH, Jansma M, Schroder CP, Sleijfer DT, Giethema JA: Weakness and numbness after chemotherapy for metastatic non-semimoma testis: a new neurological complication. Acta Oncol. 2008, 47:1596-1568. 10.1080/0284107070157320
8. National Comprehensive Cancer Network - Bone Cancer (Version 1.2020). Accessed: July 1, 2020: http://www.nccn.org/professionals/physician_gls/pdf/bone.pdf
9. Bernthal NM, Federman N, Eilber FR, et al.: Long-term results (>25 years) of a randomized, prospective clinical trial evaluating chemotherapy in patients with high-grade, operable osteosarcoma. Cancer. 2012, 118:5888-5895.
10. Addington J, Freimer M: Chemotherapy-induced peripheral neuropathy: an update on the current understanding. F1000Res. 2016, 5:10.12688/f1000research.8053.1
11. Krarup-Hansen A, Helweg-Larsen S, Schmalbruch H, Raeth M, Krarup C: Neuronal involvement in cisplatin
12. Christodoulou C, Anastasopoulos D, Visvikis A, et al.: Guillain-Barre syndrome in a patient with metastatic colon cancer receiving oxaliplatin-based chemotherapy. Anticancer Drugs. 2004, 15:997-999. 10.1097/00001813-200411000-00010
13. Cicero G, Fulfar F, Caraceni A, et al.: A case of Guillain-Barré syndrome in a patient with non small cell lung cancer treated with chemotherapy. J Chemother. 2006, 18:325-327. 10.1179/joc.2006.18.3.325
14. Koshikawa H, Tsukie T, Kurita A, et al.: Guillain-Barré syndrome in a patient with renal cell carcinoma following the first course of pazopanib therapy. J Infect Chemother. 2017, 23:798-799. 10.1016/j.jiac.2017.04.014
15. Kim MH, Hwang MS, Park Y, et al.: Paraneoplastic Guillain-Barré syndrome in small cell lung cancer. Case Rep Oncol. 2015, 8:295-300. 10.1159/000457795
16. Pappa E, Berzero G, Herlin B, et al.: Guillain-Barré syndrome during platinum-based chemotherapy: a case series and review of the literature. Oncologist. 2020, 25:194-197. 10.1634/theoncologist.2019-0255
17. Terenghi F, Ardolino G, Nobile-Orazio E: Guillain-Barre syndrome after combined CHOP and rituximab therapy in non-Hodgkin lymphoma. J Peripher Nerv Syst. 2007, 12:142-145. 10.1111/j.1529-8027.2007.00134.x
18. Hughes CL, Yorio JT, Kovitz C, Oki Y: Treatment decisions in a man with Hodgkin lymphoma and Guillain-Barre syndrome: a case report. J Med Case Rep. 2014, 8:455. 10.1186/1752-1947-8-455
19. Yang B, Lian Y, Liu Y, Wu BY, Duan RS: A retrospective analysis of possible triggers of Guillain-Barre syndrome. J Neuroimmunol. 2016, 293:17-21. 10.1016/j.jneuroim.2016.02.003
20. Rees H: Paraneoplastic syndromes: when to suspect, how to confirm, and how to manage . J Neurol Neurosurg Psychiatry. 2004, 75:45-50. 10.1136/jnnp.2004.040378